Language
Onward completes first

Blog

HomeHome / Blog / Onward completes first
search

May 05, 2023

Apple Mac Pro offers M2 Ultra and PCIe Gen 4 expansion for US$7,000

May 01, 2023

Coaxial Feedthroughs for Coupling Signals into and out of Vacuum

Jul 05, 2023

5 Reasons to Upgrade to the 11th Gen Kindle Paperwhite

Aug 02, 2023

Fairview Microwave Launches Waveguide Power Amplifiers Covering High mm

Aug 13, 2023

Getting Fired: Amazon (AMZN), Goldman (GS) and Microsoft (MSFT) Cut Jobs

Send your inquiry
SUBMIT

Sep 12, 2023

Onward completes first

May 15, 2023 By Sean Whooley Eindhoven, the Netherlands-based Onward designed

May 15, 2023 By Sean Whooley

Eindhoven, the Netherlands-based Onward designed the lead to restore movement, function and independence in people with spinal cord injury (SCI).

The company developed ARC-IM to deliver targeted electrical pulses to the spinal cord. It represents a key component of the Onward ARC-IM system engineered to deliver ARC therapy to address multiple indications. The lead works in combination with the ARC-IM neurostimulator (IPG). Onward purpose-built it for placement along the spinal cod to stimulate the dorsal roots with specific parameters outlined for each anatomical location.

According to a news release, Onward has a portfolio of these leads in many shapes, sizes and electrode arrays under development. Future indications the company may explore include blood pressure management, mobility, upper extremity function and bladder control.

Dr. Jocelyne Bloch, a neurosurgeon at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, implanted the first ARC-IM lead. The implant took place to benefit a patient with poor blood pressure regulation following SCI. Bloch placed the lead in the "hemodynamic hotspot" along the thoracic spinal cord.

ARC-IM therapy received FDA breakthrough device designation in 2021 for this indication. Onward reported positive interim results from the first ten people treated with targeted ARC-IM therapy in December 2022. Those patients needed blood pressure regulation improvements following SCI. All participants reported improved quality of life, Onward said.

"The purpose-designed ARC-IM Lead will unlock our ability to optimally deliver ARC Therapy to address many of the challenges faced by people with spinal cord injury," said Dave Marver, CEO of Onward. "We look forward to using the lead to pursue restoration of mobility and other indications in the future."

Filed Under: Blood Management, Clinical Trials, Featured, Implants, Neurological, Neuromodulation/Neurostimulation, News Well, Spine Tagged With: Onward Medical